Value of innovation for hematologic malignancies

References

• NCIN. National Cancer Intelligence Network. 2013. www.ncin.org.uk/view?rid=1787. National Cancer Research Institute. Public Health England. Accessed October 15, 2015
   Google Scholar
• Sant M, Minicozzi P, Mounier M, et al; EUROCARE-5 Working Group. Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study. Lancet Oncol 2014;15:931-42
   PubMed Web of Science ®Google Scholar
• Munro AJ. Leukaemia and lymphoma: why has survival improved? Lancet Oncol 2014;15:906-7
   PubMed Web of Science ®Google Scholar
• Lichtenberg FR. The impact of pharmaceutical innovation on premature cancer mortality in Switzerland, 1995–2012. Eur J Health Econ 2015;Sep 5. [Epub ahead of print] DOI 10.1007/s10198-015-0725-6
   PubMed Web of Science ®Google Scholar
• Lichtenberg FR. The impact of pharmaceutical innovation on premature cancer mortality in Canada, 2000–2011. Int J Health Econ Manag 2015;published online 26 June 2015 DOI 10.1007/s10754-015-9172-2
   Google Scholar
• Kumar SK, Dispenzieri A, Lacy MQ, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 2014;28:1122-8
   PubMed Web of Science ®Google Scholar
• Wang BC, Gross CP, Frick K, et al. The impact of hypomethylating agents on the cost of care and survival of elderly patients with myelodysplastic syndromes. Leuk Res 2012;36:1370-5
   PubMed Web of Science ®Google Scholar
• Blendon RJ, Benson JM, Botta MD, et al. A four-country survey of public attitudes towards restricting healthcare costs by limiting the use of high-cost medical interventions. BMJ Open 2012;2:e001087
   Web of Science ®Google Scholar
• Mulbacher AC, Nubling M. Analysis of physicians' perspectives versus patients' preferences: direct assessment and discrete choice experiments in the therapy of multiple myeloma. Eur J Health Econ 2011;12:193-203
   PubMed Web of Science ®Google Scholar
• Schnipper LE, Davidson NE, Wollins DS, et al. American Society of Clinical Oncology Statement: a conceptual framework to assess the value of cancer treatment options. J Clin Oncol 2015;33:2563-77
   PubMed Web of Science ®Google Scholar
• Associatin for Value-Based Cancer Care. 2015. Cranbury, NJ. http://wwwavbcconlineorg. Accessed August 20, 2015
   Google Scholar
• Harrison CN, Mesa RA, Kiladjian JJ, et al. Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. Br J Haematol 2013;162:229-39
   PubMed Web of Science ®Google Scholar
• Annemans L, Francis A, Olivier B, et al. World Health Organization. A call to make valuable innovative medicines accessible in the European Union Recommendations for a coordinated action to stimulate, measure and valorise pharmaceutical innovation Background report for the ministerial conference 23-24 September 2010; July 2, 2010 Accessed 2015.
   Google Scholar
• Garber G, Gates SM, Blume-Kohout ME, et al. Challenges to value-enhancing innovation in health-care delivery. Commonalities and contrasts with innovation in drugs and devices. OP 341. www.rand.org. Accessed August 20, 2015 RAND Corporation, 2011. Santa Monica, CA. Library of Congress Control Number: 2011938451. ISBN: 978-0-8330-5907-9.
   Google Scholar
• Beresniak A, Medina-Lara A, Auray JP, et al. Validation of the underlying assumptions of the quality-adjusted life-years outcome: results from the ECHOUTCOME European project. Pharmacoeconomics 2015;33:61-9
   PubMed Web of Science ®Google Scholar
• Shillcutt SD, Walker DG, Goodman CA, et al. Cost-effectiveness in low- and middle-income countries. A review of the debbates surrounding decision rules. Pharmacoeconomics 2009;27:903-17
   PubMed Web of Science ®Google Scholar
• Saret CJ, Winn AN, Shah G, et al. Value of innovation in hematologic malignancies: a systematic review of published cost-effectiveness analyses. http://www.ncbi.nlm.nih.gov.bvs.cilea.it/pubmed Blood 2015;125:1866-9
   PubMed Web of Science ®Google Scholar
• Chhatwal J, Mathisen M, Kantajian H. Are high drug prices for hematologic malignancies justified? A critical analysis. Cancer 2015;121:3372–9 (in press)
   PubMed Web of Science ®Google Scholar
• Pasdera A. I costi standard dei ricoveri in Ematologia, Società Italiana di Ematologia, Il Sole 24 Ore Sanità, 12th November 2013; 6-7. www.costistandard.com. Accessed July 30, 2015
   Google Scholar
• Lin P-J, Winn A, Parsons SK, et al. Is the high cost of CML care “worth it"? J Clin Oncol 2015;33(Suppl):abstr e17801
   Google Scholar
• Wang BC, Gross CP, Frick K, et al. The impact of hypomethylating agents on the cost of care and survival of elderly patients with myelodysplastic syndromes. Leuk Res 2012;36:1370-5
   PubMed Web of Science ®Google Scholar
• Schulman KL, Kohles J. Economic burden of metastatic bone disease in the U.S. Cancer 2007;109:2334-42
   PubMed Web of Science ®Google Scholar
• Gidwani R, Khan ZM, Fenau P, et al. A cost-effectiveness analysis of using azacitidine vs decitabine in treating patients with myelodysplastic syndromes. J Med Econ 2012;15:145-54
   PubMedGoogle Scholar
• Usmani SZ, Cavenagh JD, Belch AR, et al. Cost-effectiveness of lenalidomide plus dexamethasone vs bortezomib plus melphalan and prednisone in transplant-ineligible US patients with newly-diagnosed multiple myeloma. J Med Econ 2015;1-16 17 Nov 2015
   PubMed Web of Science ®Google Scholar
• Marchetti M, Cuneo A, Montillo M, et al. Cost-effectiveness of R-idelalisib versus standard of care in relapsed or refractory CLL. Leuk Lymphoma 2015. Abstract from the XVI International Workshop on Chronic Lymphocytic Leukemia. 140 (Abstract #86)
   Google Scholar
• Abboud C, Berman E, Cohen A, et al. Experts in chronic myeloid leukemia. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood 2013;12:4439-42
   Web of Science ®Google Scholar
• Paddock S, Brum L, Sorrow K, et al. The PACE continuous innovation Indicators: a flexible tool to evaluate progress in cancer treatments. J Clin Oncol 2015;33(Suppl):abstr e17783
   Google Scholar
• International Society for Pharmacoeconomics and Outcomes Research. ISPOR 505 Lawrence Square Blvd. South Lawrenceville, NJ http://www.ispor.org/mission.asp. Accessed August 20, 2015
   Google Scholar
• Haematological Malignancy Research Network. University of York. https://www.hmrn.org/economics/models. Accessed November 10, 2015
   Google Scholar
• The Italian Code of Medical Deontology, 2014, 6th article. Federazione Nazionale degli Ordini dei Medici Chirurghi e degli Odontoiatri, Roma, Italy.http://www.fnomceo.it/fnomceo/Codice+di+Deontologia+Medica+2014.html?t=a&id=115184. Accessed August 20, 2015
   Google Scholar
• Brunetti M, Shemilt I, Pregno S, et al. GRADE guidelines: 10. Considering resource use and rating the quality of economic evidence. J Clin Epidemiol 2013;66:140-50
   PubMed Web of Science ®Google Scholar